3 completed, 2 terminated, 1 recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow rhIL-15: new trials by email Literature Review of rhIL-15 trials Research Report on rhIL-15
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma rhIL-15, Dinituximab, Temozolomide - Neuroblastoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2025-10-21 | 2026-10-21 |
| Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma rhIL-15, Avelumab - Clear-Cell Renal Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2020-05-26 | 2022-05-17 |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia rhIL-15, Obinutuzumab - Leukemia, Lymphocytic | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2019-07-11 | 2022-03-22 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies rhIL-15, Avelumab - Peripheral T-cell Lymphoma NOS, Mycosis Fungoides | Phase 1 | Completed | National Cancer Institute (NCI) | 8 | 2019-06-07 | 2022-09-13 |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers rhIL-15, Ipilimumab, Nivolumab - Metastatic Solid Tumors, Treatment-Refractory Cancers | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2018-02-05 | 2025-12-18 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15 - Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2013-02-15 | 2017-09-15 |
Carcinoma, Renal Cell (2) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Melanoma (1) · Mycosis Fungoides (1) · Neuroblastoma (1) · Sezary Syndrome (1) · Squamous Cell Carcinoma of Head and Neck (1)
National Cancer Institute (NCI) (6)
United States (6)
Kevin C Conlon, M.D. (3) · Hong Ha Rosa Nguyen, M.D. (1) · Jeffrey Miller (1) · Jibran Ahmed, M.D. (1)
PMID 32508818, PMID 33883258, PMID 29203590, PMID 30045932
U01CA154967 (1)